As global markets navigate geopolitical tensions, the accelerating energy transition, artificial intelligence expansion, and persistent supply constraints, commodity prices are…
AbbVie has successfully navigated the loss of exclusivity for its blockbuster Humira by building a powerful growth engine around Skyrizi (risankizumab) and Rinvoq (upadacitinib).…
France faces a striking contradiction. Its public debt has climbed to levels not seen since the aftermath of World War II, deficits remain stubbornly high, and borrowing costs…
As of mid-October 2026, oil markets remain under significant pressure. West Texas Intermediate (WTI) is trading near $92–93 per barrel, while Brent crude hovers around $105–107.…
As the third-quarter 2026 earnings season gains momentum in mid-October, analysts project robust year-over-year profit growth for S&P 500 companies. Consensus estimates point to…
PepsiCo, Inc. (NASDAQ: PEP) reported third-quarter 2026 results on October 8 that exceeded Wall Street expectations on both revenue and adjusted earnings, driven by accelerating…
Bitcoin has already delivered one of its strongest third-quarter performances in years, climbing roughly 40-50% from mid-2026 lows near $58,000 to levels above $86,000. As the…
Chinese electric and electrified vehicles have gone from being a residual curiosity to one of the most disruptive forces in the European automotive market. In just a few years…
AbbVie Inc. (NYSE: ABBV) has successfully navigated the sharp decline of its former blockbuster Humira following loss of exclusivity and biosimilar competition. The company is…
Europe’s public pension systems, mostly built on the pay-as-you-go (PAYG) model, function in practice like a vast, state-sanctioned Ponzi scheme. Current workers’ contributions…